{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-035944","form_type":"8-K","ticker":"OTLC","cik":"0000908259","company_name":"Oncotelic Therapeutics, Inc.","filed_at":"2022-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.962086+00:00","generated_at":"2026-06-21T02:16:57.573271+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oncotelic presents clinical data confirming TGF-β2 as target for gliomas; OS improvements shown","bullets":["Reduced TGF-β2 increased OS from 9 to 22 mos in pediatric brainstem patients (N=95, p<0.0001).","In glioma patients treated with TMZ, reduced TGF-β2 improved OS from 25 to 94 mos (N=230, p<0.0001).","Similar OS improvement from 25 to 94 mos with radiation therapy (N=293, p<0.0001).","Company states failure of GSK's bintrafusp alfa (TGF-β1 trap) validates focus on TGF-β2 isoform.","Data presented at AACR-JCA Joint Conference Dec 10-14, 2022 in Maui."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-035944","json":"https://secwatch.observer/filing/0001493152-22-035944.json","markdown":"https://secwatch.observer/filing/0001493152-22-035944.md","text":"https://secwatch.observer/filing/0001493152-22-035944.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/908259/000149315222035944/0001493152-22-035944-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/908259/000149315222035944/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T02:16:57.573271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}